{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:29:26Z","timestamp":1794360566437,"version":"4.9.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02957-z","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T05:02:44Z","timestamp":1724130164000},"page":"3757-3770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners"],"prefix":"10.1007","volume":"41","author":[{"given":"Pamela","family":"Kushner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cebri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Deed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2957_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74\u00a0million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.","journal-title":"Lancet Reg Health Eur"},{"key":"2957_CR2","first-page":"21","volume":"7","author":"SD Fraser","year":"2016","unstructured":"Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. Pragmat Obs Res. 2016;7:21\u201332.","journal-title":"Pragmat Obs Res"},{"issue":"2","key":"2957_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1053\/j.ajkd.2020.01.007","volume":"76","author":"CD Chu","year":"2020","unstructured":"Chu CD, McCulloch CE, Banerjee T, et al. CKD awareness among US adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2957_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067386","volume":"13","author":"N Tangri","year":"2023","unstructured":"Tangri N, Moriyama T, Schneider MP, et al. Prevalence of undiagnosed stage\u00a03 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13(5):e067386.","journal-title":"BMJ Open"},{"issue":"1","key":"2957_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12882-020-01792-y","volume":"21","author":"GA Nichols","year":"2020","unstructured":"Nichols GA, D\u00e9ruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, Hauske SJ. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs without type\u00a02 diabetes. BMC Nephrol. 2020;21(1):167.","journal-title":"BMC Nephrol"},{"key":"2957_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14282","author":"N Tangri","year":"2024","unstructured":"Tangri N, Alvarez CS, Arnold M, Barone S, Cebri\u00e1n A, Chen H, et al. Suboptimal monitoring and management in patients with unrecorded stage\u00a03 chronic kidney disease in real-world settings: insights from REVEAL-CKD. Eur J Clin Invest. 2024. https:\/\/doi.org\/10.1111\/eci.14282.","journal-title":"Eur J Clin Invest"},{"key":"2957_CR7","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"6","key":"2957_CR8","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s12325-023-02482-5","volume":"40","author":"N Tangri","year":"2023","unstructured":"Tangri N, Peach EJ, Franz\u00e9n S, Barone S, Kushner PR. Patient management and clinical outcomes associated with a recorded diagnosis of stage\u00a03 chronic kidney disease: the REVEAL-CKD study. Adv Ther. 2023;40(6):2869\u201385.","journal-title":"Adv Ther"},{"issue":"5","key":"2957_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41581-020-0268-7","volume":"16","author":"EF Carney","year":"2020","unstructured":"Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251.","journal-title":"Nat Rev Nephrol"},{"issue":"9889","key":"2957_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352.","journal-title":"Lancet"},{"issue":"3","key":"2957_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1053\/j.ajkd.2018.10.007","volume":"73","author":"WR Verberne","year":"2019","unstructured":"Verberne WR, Das-Gupta Z, Allegretti AS, et al. Development of an international standard set of value-based outcome measures for patients with chronic kidney disease: a report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. Am J Kidney Dis. 2019;73(3):372\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2957_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41581-023-00747-4","volume":"19","author":"C Zoccali","year":"2023","unstructured":"Zoccali C, Mark PB, Sarafidis P, et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease. Nat Rev Nephrol. 2023;19(11):733\u201346.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2957_CR13","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.3390\/ijms24032988","volume":"24","author":"M Szlagor","year":"2023","unstructured":"Szlagor M, Dybiec J, M\u0142ynarska E, Rysz J, Franczyk B. Chronic kidney disease as a comorbidity in heart failure. Int J Mol Sci. 2023;24(3):2988.","journal-title":"Int J Mol Sci"},{"issue":"704","key":"2957_CR14","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.3399\/bjgp20X714125","volume":"71","author":"C MacRae","year":"2021","unstructured":"MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract. 2021;71(704):e243\u20139.","journal-title":"Br J Gen Pract"},{"issue":"Suppl\u00a01","key":"2957_CR15","first-page":"4529","volume":"38","author":"S Chadban","year":"2023","unstructured":"Chadban S, Esposito C, Rangaswami J, Wu M-S, Hull R, Elsayed H, et al. #4529 PACE-CKD: Financial burden and work productivity of patients with CKD and caregivers: results from a US survey. Nephrol Dial Transplant. 2023;38(Suppl\u00a01):4529.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"2957_CR16","first-page":"3990","volume":"38","author":"C Esposito","year":"2023","unstructured":"Esposito C, Chadban S, Rangaswami J, et al. #3990 PACE-CKD: Health-related quality of life of patients with CKD and caregivers: results from a US survey. Nephrol Dial Transplant. 2023;38(Suppl\u00a01):3990.","journal-title":"Nephrol Dial Transplant"},{"key":"2957_CR17","doi-asserted-by":"crossref","unstructured":"Carrero J, Pollock C, Kanda E, et al. #3393 Patient-reported outcomes in early versus advanced chronic kidney disease: evidence from baseline data in the discover CKD prospective study. Nephrol Dial Transplant. 2023;38.","DOI":"10.1093\/ndt\/gfad063c_3393"},{"issue":"8","key":"2957_CR18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2215\/CJN.00060119","volume":"14","author":"SL Tummalapalli","year":"2019","unstructured":"Tummalapalli SL, Powe NR, Keyhani S. Trends in quality of care for patients with CKD in the United States. Clin J Am Soc Nephrol. 2019;14(8):1142\u201350.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2957_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"2957_CR20","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha V, Al-Ghamdi SMG, Li G, et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv Ther. 2023;40(10):4405\u201320.","journal-title":"Adv Ther"},{"key":"2957_CR21","unstructured":"World Health Organization: Reducing noncommunicable diseases: a signature roadmap for the WHO European Region. https:\/\/www.who.int\/europe\/publications\/i\/item\/WHO-EURO-2022-6620-46386-67147. Accessed July 2023."},{"key":"2957_CR22","unstructured":"ISN Global Kidney Health Atlas. https:\/\/www.theisn.org\/initiatives\/global-kidney-health-atlas\/. Accessed 2023."},{"key":"2957_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473.","journal-title":"Nat Rev Nephrol"},{"key":"2957_CR24","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1136\/bmj.p2327","volume":"383","author":"K Khunti","year":"2023","unstructured":"Khunti K, Sathanapally H, Mountain P. Multiple long term conditions, multimorbidity, and co-morbidities: we should reconsider the terminology we use. BMJ. 2023;383:2327.","journal-title":"BMJ"},{"issue":"3","key":"2957_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ndt\/gfac283","volume":"38","author":"R Nee","year":"2023","unstructured":"Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2023;38(3):532\u201341.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2957_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221325","volume":"14","author":"CJ Sperati","year":"2019","unstructured":"Sperati CJ, Soman S, Agrawal V, et al. Primary care physicians\u2019 perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. PLoS ONE. 2019;14(8):e0221325.","journal-title":"PLoS ONE"},{"issue":"7","key":"2957_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/dom.14684","volume":"24","author":"K Khunti","year":"2022","unstructured":"Khunti K, Jabbour S, Cos X, et al. Sodium-glucose co-transporter-2 inhibitors in patients with type\u00a02 diabetes: barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab. 2022;24(7):1187\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2957_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","volume":"79","author":"C Delgado","year":"2022","unstructured":"Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268\u201388.e1.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2957_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100851","volume":"6","author":"M Madero","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024;6(8):100851.","journal-title":"Kidney Med"},{"issue":"11","key":"2957_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type\u00a02 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2957_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1053\/j.ajkd.2013.12.012","volume":"63","author":"P Komenda","year":"2014","unstructured":"Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789\u201397.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2957_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/M22-3228","volume":"176","author":"MM Cusick","year":"2023","unstructured":"Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-wide screening for chronic kidney disease: a cost-effectiveness analysis. Ann Intern Med. 2023;176(6):788\u201397.","journal-title":"Ann Intern Med"},{"key":"2957_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hyperten. 2023. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hyperten"},{"key":"2957_CR34","doi-asserted-by":"crossref","unstructured":"Mark PB, Sarafidis P, Ekart R, et al. SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38(11):2444\u201355.","DOI":"10.1093\/ndt\/gfad112"},{"issue":"1","key":"2957_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2215\/CJN.01290216","volume":"12","author":"EB Schroeder","year":"2017","unstructured":"Schroeder EB, Yang X, Thorp ML, et al. Predicting 5-year risk of RRT in stage\u00a03 or 4 CKD: development and external validation. Clin J Am Soc Nephrol. 2017;12(1):87\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2957_CR36","first-page":"482","volume":"34","author":"ME Grams","year":"2023","unstructured":"Grams ME, Brunskill NJ, Ballew SH, et al. The kidney failure risk equation: evaluation of novel input variables including eGFR estimated using the CKD-EPI 2021 equation in 59 cohorts. J Am Soc Nephrol. 2023;34(3):482\u201394.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2957_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002955","volume":"16","author":"RW Major","year":"2019","unstructured":"Major RW, Shepherd D, Medcalf JF, Xu G, Gray LJ, Brunskill NJ. The kidney failure risk equation for prediction of end stage renal disease in UK primary care: an external validation and clinical impact projection cohort study. PLoS Med. 2019;16(11):e1002955.","journal-title":"PLoS Med"},{"issue":"2","key":"2957_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.ajkd.2021.05.018","volume":"79","author":"HU Zacharias","year":"2022","unstructured":"Zacharias HU, Altenbuchinger M, Schultheiss UT, et al. A predictive model for progression of CKD to kidney failure based on routine laboratory tests. Am J Kidney Dis. 2022;79(2):217\u201330.e1.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2957_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/ajkd.2001.26850","volume":"38","author":"MJ Landray","year":"2001","unstructured":"Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis. 2001;38(3):537\u201346.","journal-title":"Am J Kidney Dis"},{"key":"2957_CR40","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801."},{"issue":"19","key":"2957_CR41","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter\u00a02 inhibitors and risk of hyperkalemia in people with type\u00a02 diabetes: a meta-analysis of individual participant data from randomized controlled trials. Circulation. 2022;145(19):1460\u201370.","journal-title":"Circulation"},{"issue":"20","key":"2957_CR42","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456\u201362.","journal-title":"N Engl J Med"},{"issue":"12","key":"2957_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"2957_CR44","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2957_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E, Rastogi A, Murohara T, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24(1):18.","journal-title":"BMC Nephrol"},{"issue":"4S","key":"2957_CR46","first-page":"S1","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1\u2013115.","journal-title":"Kidney Int"},{"issue":"4S","key":"2957_CR47","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"7","key":"2957_CR48","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2957_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"2957_CR50","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"24","key":"2957_CR51","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"2957_CR52","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"2957_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"2957_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.34067\/KID.0000000000000374","volume":"5","author":"N Tangri","year":"2024","unstructured":"Tangri N, Svensson MK, Bodeg\u00e5rd J, et al. Mortality, health care burden, and treatment of CKD: a multinational, observational study (OPTIMISE-CKD). Kidney. 2024;5(3):352\u201362.","journal-title":"Kidney"},{"issue":"5","key":"2957_CR55","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type\u00a02 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2957_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","volume":"12","author":"KY Thong","year":"2018","unstructured":"Thong KY, Yadagiri M, Barnes DJ, et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter\u00a02 inhibitor treatment: the ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2018;12(1):45\u201350.","journal-title":"Prim Care Diabetes"},{"issue":"8","key":"2957_CR57","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","volume":"16","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol. 2021;16(8):1284\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2957_CR58","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1111\/dom.14805","volume":"24","author":"K Khunti","year":"2022","unstructured":"Khunti K, Aroda VR, Bhatt DL, et al. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: a perspective based on the updated evidence. Diabetes Obes Metab. 2022;24(11):2071\u201380.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2957_CR59","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/ASN.2022030306","volume":"33","author":"N Jongs","year":"2022","unstructured":"Jongs N, Chertow GM, Greene T, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;33(11):2094\u2013107.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2957_CR60","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","volume":"99","author":"M Oshima","year":"2021","unstructured":"Oshima M, Jardine MJ, Agarwal R, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021;99(4):999\u20131009.","journal-title":"Kidney Int"},{"issue":"3","key":"2957_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010337","volume":"6","author":"R Simmonds","year":"2016","unstructured":"Simmonds R, Evans J, Feder G, et al. Understanding tensions and identifying clinician agreement on improvements to early-stage chronic kidney disease monitoring in primary care: a qualitative study. BMJ Open. 2016;6(3):e010337.","journal-title":"BMJ Open"},{"issue":"4","key":"2957_CR62","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s12325-024-02794-0","volume":"41","author":"PR Kushner","year":"2024","unstructured":"Kushner PR, DeMeis J, Stevens P, Gjurovic AM, Malvolti E, Tangri N. Patient and clinician perspectives: to create a better future for chronic kidney disease, we need to talk about our kidneys. Adv Ther. 2024;41(4):1318\u201324.","journal-title":"Adv Ther"},{"issue":"2","key":"2957_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5414\/CN108831","volume":"86","author":"J Wright Nunes","year":"2016","unstructured":"Wright Nunes J, Roney M, Kerr E, Ojo A, Fagerlin A. A diagnosis of chronic kidney disease: despite fears patients want to know early. Clin Nephrol. 2016;86(2):78\u201386.","journal-title":"Clin Nephrol"},{"issue":"1","key":"2957_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ekir.2023.10.019","volume":"9","author":"M Alexiuk","year":"2024","unstructured":"Alexiuk M, Elgubtan H, Tangri N. Clinical decision support tools in the electronic medical record. Kidney Int Reports. 2024;9(1):29\u201338.","journal-title":"Kidney Int Reports"},{"issue":"8","key":"2957_CR65","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2337\/dc19-2243","volume":"43","author":"A Willis","year":"2020","unstructured":"Willis A, Crasto W, Gray LJ, et al. Effects of an electronic software \u201cprompt\u201d with health care professional training on cardiovascular and renal complications in a multiethnic population with type\u00a02 diabetes and microalbuminuria (the GP-Prompt Study): results of a pragmatic cluster-randomized trial. Diabetes Care. 2020;43(8):1893\u2013901.","journal-title":"Diabetes Care"},{"issue":"8","key":"2957_CR66","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40620-022-01353-6","volume":"35","author":"F Pesce","year":"2022","unstructured":"Pesce F, Pasculli D, Pasculli G, et al. \u201cThe Disease Awareness Innovation Network\u201d for chronic kidney disease identification in general practice. J Nephrol. 2022;35(8):2057\u201365.","journal-title":"J Nephrol"},{"issue":"1","key":"2957_CR67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40620-022-01340-x","volume":"36","author":"C Wanner","year":"2023","unstructured":"Wanner C, Schuchhardt J, Bauer C, et al. Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. J Nephrol. 2023;36(1):45\u201354.","journal-title":"J Nephrol"},{"key":"2957_CR68","unstructured":"Advancing American Kidney Health. https:\/\/www.federalregister.gov\/documents\/2019\/07\/15\/2019-15159\/advancing-american-kidney-health. Accessed Oct 2023."},{"issue":"11","key":"2957_CR69","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10157-019-01786-7","volume":"23","author":"A Fukui","year":"2019","unstructured":"Fukui A, Yokoo T, Nangaku M, Kashihara N. New measures against chronic kidney diseases in Japan since 2018. Clin Exp Nephrol. 2019;23(11):1263\u201371.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"2957_CR70","first-page":"273","volume":"28","author":"R Alc\u00e1zar","year":"2008","unstructured":"Alc\u00e1zar R, Egocheaga MI, Orte L, et al. SEN-SEMFYC consensus document on chronic kidney disease. Nefrologia. 2008;28(3):273\u201382.","journal-title":"Nefrologia"},{"issue":"3","key":"2957_CR71","first-page":"302","volume":"34","author":"M Gorostidi","year":"2014","unstructured":"Gorostidi M, Santamar\u00eda R, Alc\u00e1zar R, et al. Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. Nefrologia. 2014;34(3):302\u201316.","journal-title":"Nefrologia"},{"issue":"6","key":"2957_CR72","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/ckj\/sfab061","volume":"14","author":"SN van der Veer","year":"2021","unstructured":"van der Veer SN, Couchoud C, Morton RL. The role of kidney registries in expediting large-scale collection of patient-reported outcome measures for people with chronic kidney disease. Clin Kidney J. 2021;14(6):1495\u2013503.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2957_CR73","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/ndt\/gfab252","volume":"37","author":"KJ Jager","year":"2021","unstructured":"Jager KJ, \u00c5sberg A, Collart F, et al. A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy. Nephrol Dial Transplant. 2021;37(1):8\u201313.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02957-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02957-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02957-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T13:03:02Z","timestamp":1726232582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02957-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2957"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02957-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana Cebri\u00e1n has received grants from Merck Sharp & Dohme and speaker honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Mundipharma, Novartis Pharmaceuticals, Novo Nordisk, and Sanofi. Gary Deed reports advisory board fees from AstraZeneca and Boehringer Ingelheim, as well as non-financial involvement in the START Trial (The George Institute) of SGLT2 inhibitors as first-line therapy to improve renal outcomes in T2D. He is a consultant to Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, and Sequiris. Kamlesh Khunti has received consultancy fees from Amgen, AstraZeneca, Bristol Myers-Squibb, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi, Servier, Pfizer, Roche, Daiichi-Sankyo, Embecta, and Nestl\u00e9 Health Science; research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Roche, Sanofi, Servier, Oramed Pharmaceuticals, Daiichi-Sankyo, and Applied Therapeutics; and speaker\u2019s bureau fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Sanofi, Servier, and Roche. Pamela Kushner has received speaker\u2019s bureau and advisory board fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk A\/S; speaker\u2019s fees from Bayer AG and Boehringer Ingelheim; and honoraria from AstraZeneca and Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}